Antifungal activity of saperconazole (R 66 905) in vitro
- 1 October 1989
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 24 (4) , 533-537
- https://doi.org/10.1093/jac/24.4.533
Abstract
Saperconazole, a novel orally active triazole antifungal, inhibited Candida spp., Aspergilhis spp. and dermatophyte fungi in vitro. Its minimal inhibitory concentrations for Candida spp. and dermatophytes were relatively high, like those of comparable triazole antifungals, but all of the Aspergillus isolates tested were inhibited by less than 0·1 mg/l. Relative inhibition factors of saperconazole were in the range 31–76% for Candida isolates, 6–18% for Aspergillus isolates and 5–10% for dermatophytes. These figures predict a good inhibitory activity of saperconazole for all the fungi tested, with particularly strong activity against Aspergillus spp. and dermatophytes. Saperconazole inhibited hyphal branch formation in C. albicans at concentrations as low as 108 M.Keywords
This publication has 4 references indexed in Scilit:
- Antifungal effects of fluconazole (UK 49858), a new triazole antifungal, in vitroJournal of Antimicrobial Chemotherapy, 1986
- Effects of Imidazole- and Triazole-derivative Antifungal Compounds on the Growth and Morphological Development of Candida albicans HyphaeMicrobiology, 1985
- Antifungal relative inhibition factors: BAY 1–9139, bifonazole, butoconazole, isoconazole, itraconazole (R 51211), oxiconazole, Ro 14–4767/002, sulconazole, terconazole and vibunazole (BAY n-7133) compared in vitro with nine established antifungal agentsJournal of Antimicrobial Chemotherapy, 1984
- Relative inhibition factors—a novel approach to the assessment of antifunga antibiotics in vitroJournal of Antimicrobial Chemotherapy, 1984